

JHL Biotech appoints Rong Chen as CMO

02 January 2018 | News

Dr. Chen joins the company from his previous role as Chief Medical Officer at Phagelux, a biologics company in Shanghai.



Taiwan based biopharmaceutical startup JHL Biotech Inc. has appointed Dr. Rong Chen as the Chief Medical Officer (CMO). As CMO, Dr. Chen will oversee JHL's medical and clinical development work as part of its mission to make world-class biopharmaceuticals affordable and available to more patients. Dr. Chen joins the company from his previous role as Chief Medical Officer at Phagelux, a biologics company in Shanghai.

Prior to Phagelux, Dr. Chen was Chief Medical Officer at CASI Pharmaceuticals, Vice President and Head of Regulatory Excellence for China/HK area at GlaxoSmithKline, Medical Director for the Asia Pacific region at Beyer Schering Pharma, and Medical Director for China at Sanofi. He also previously held several clinical and research positions in Australia.

Dr. Chen received his PhD from the Royal Adelaide Hospital, University of Adelaide in Australia and both his bachelor's and master's in medicine from Shandong Medical University in China.

JHL Biotech was founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank.